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Abstract
Background: The incidence of type 2 diabetes, cardiovascular diseases, and obesity has been rising dramatically;
however, their pathogenesis is particularly intriguing. Recently, dysbiosis of the intestinal microbiota has emerged as
a new candidate that may be linked to metabolic diseases. We hypothesize that selective modulation of the
intestinal microbiota by probiotic or synbiotic supplementation may improve metabolic dysfunction and prevent
diabetes in prediabetics. In this study, a synthesis and study of synbiotics will be carried out for the first time in Iran.
Methods/Design: In a randomized triple-blind controlled clinical trial, 120 adults with impaired glucose tolerance
based on the inclusion criteria will be selected by a simple random sampling method and will be randomly
allocated to 6 months of 6 g/d probiotic, synbiotic or placebo. The fecal abundance of bacteria, blood pressure,
height, weight, and waist and hip circumferences will be measured at baseline and following treatment. Also,
plasma lipid profiles, HbA1C, fasting plasma glucose, and insulin levels, will be measured and insulin resistance
(HOMA-IR) and beta-cell function (HOMA-B) will be calculated at baseline and will be repeated at months 3, 6, 12,
and 18. The data will be compared within and between groups using statistical methods.
Discussion: The results of this trial could contribute to the evidence-based clinical guidelines that address gut microbiota
manipulation to maximize health benefits in prevention and management of metabolic syndrome in prediabetes.
Trial registration: Iranian Registry of Clinical Trials: IRCT201511032321N2. Registered on 27 February 2016.
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Background
Diabetes mellitus (DM), prediabetes, obesity, and cardiovas-
cular disorders (CVD) are important public health prob-
lems in that their prevalence and incidence have been
rising dramatically during the last decades [1]. The preva-
lence of prediabetes in the world exceeds 25% who are at
higher risk of developing type 2 diabetes (T2DM), com-
pared with individuals with normal glucose tolerance [2].
In addition to well-established risk factors for T2DM and
CVD, including genetic predisposition and unhealthy life-
style, an altered configuration of the microbial community
in the gut has emerged as a new candidate that may be
linked to these metabolic disorders [2, 3]. Studies suggest
that aspects of the modern Western lifestyle, including
high-fat diets and antibiotics, can alter commensal micro-
bial communities. However, a full list of factors which are
capable of altering gut microbiota remains incomplete [4].
Studies have shown that early intervention in patients with
impaired glucose tolerance can significantly prevent type 2
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diabetes [3]. Recent researches suggest that intestinal
microbiota (i.e., Bacteria, Archaea and Eukarya residing in
the gastrointestinal tract) are associated with low-grade
chronic inflammation and may play a role in the pathogen-
esis of obesity- and cardiovascular disease -related events
[5, 6]. The role of gut microbiota in metabolic disorders
may be through influence on host nutrition and energy,
intestinal epithelial homeostasis, and host immune system
[7]. It is shown that endotoxin concentrations are higher in
adults at risk of T2DM compared with normoglycemic in-
dividuals and are associated with an increased risk of insu-
lin resistance, CVD, and incidence of type 2 diabetes [8, 9].
The distal gut microbiota is composed of billions of
bacteria, of which Bacteroidetes and Firmicutes are the
two dominant phylogenetic types [10]. Firmicutes are
the largest phylum of bacteria, comprising more than
200 genera, and the Bacteroidetes include over 20 bac-
terial genera [11]. Most of the studies in humans and in
mice have reported that obesity and impaired glucose
metabolism are associated with an altered ratio of Firmi-
cutes and Bacteroidetes [12, 13].
It is documented that the ratio of Bacteroidetes to Fir-
micutes is positively and significantly correlated with
plasma glucose concentrations [8, 14]. In a study in
mice, obesity has been associated with a 50% reduction
in Bacteroidetes and increase in Firmicutes [15].
An approach for modulation in the gut microbiota is
the use of oral viable strains of bacteria (probiotics), indi-
gestible carbohydrates (prebiotics), or synergistic combi-
nations of a probiotic and prebiotic (synbiotic) [16, 17].
Based on previous studies, prebiotics result in specific
changes in the activity and/or composition of the gut
microbiota mostly in rodent models, which can be benefi-
cial for local and systemic host health. Most health aspects
of prebiotics have been directed toward obesity and inflam-
mation [18]. Furthermore, probiotic supplementation has
been shown to reduce metabolic endotoxemia and improve
glycemic control in rodents [19]. Therefore, it is hypothe-
sized that prebiotic and/or probiotic supplementation may
be a useful strategy to improve metabolic health, insulin re-
sistance, and prevent type 2 diabetes, which could be inter-
esting in the management of metabolic disorders in
prediabetics. To establish the causality, well-designed and
well-powered prospective studies in which an altered
microbiome is documented during supplementation with
probiotic, prebiotic or synbiotic are needed [20]. In this
field, the evidence is limited and the results are inconsist-
ent. The discrepancies between studies can be explained by
ethnic or dietary differences. Also, knowledge on the long-
term efficacy of these treatments and comparison of their
effects in a randomized clinical trial is still lacking, espe-
cially in the human. The intervention period of most of the
previous trials has been too short (less than 3 months) to
observe the effects of these supplements. In addition, there
are limited studies which explored the effects of probiotic
or synbiotic administration in prediabetic individuals. Up to
now, there has been no clinical trial to assess the effects of
these supplements on insulin resistance and risk of diabetes
development in patients with prediabetes.
Hence, this study has been designed to investigate the
efficacy of probiotic and synbiotic administration in the
development of type 2 diabetes and metabolic variables
in prediabetics via a parallel-group randomized triple-
blind placebo-controlled clinical trial.
The aims and hypotheses
General aim
The general aim of the present investigation is to deter-
mine the effects of 6 months ingestion of probiotic or
synbiotic on metabolic syndrome indices and gut micro-
biota composition through a triple-blind, randomized,
placebo-controlled clinical trial in adults at risk of type 2
diabetes (prediabetes).
The specific aims and hypotheses
Aim 1
To determine whether probiotic or synbiotic supplementa-
tion improves fasting plasma glucose, insulin resistance
(primary outcome), and beta-cell function in individuals at
elevated risk of developing T2DM. We hypothesize that
probiotic and synbiotic supplementation will improve
fasting plasma glucose, insulin sensitivity, and beta-cell
function in these individuals compared with placebo.
Aim 2
To determine whether probiotic or synbiotic supplemen-
tation will improve lipid profiles in individuals at elevated
risk of developing T2DM. We hypothesize that probiotic
and synbiotic supplementation will reduce serum trigly-
ceride and non-high-density lipoprotein (HDL) choles-
terol, elevate HDL cholesterol, and improve low-density
lipoprotein (LDL)/HDL, total cholesterol (TC)/HDL and
triglyceride (TG)/HDL in these individuals.
Aim 3
To determine whether probiotic or synbiotic supplemen-
tation will improve anthropometric indicators in individ-
uals at elevated risk of developing T2DM. We hypothesize
that probiotic and synbiotic supplementation will improve
body mass index (BMI), waist circumference and waist-to-
hip ratio (WHR) in these individuals.
Aim 4
To determine the changes in abundance and ratio of two
dominant groups of gut microbiota including Firmicutes
and Bacteroidetes and their relation with metabolic syn-
drome indices during supplementation. We hypothesize that
the change in Gram-positive gut microbiota (Firmicutes)
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and Firmicutes-to-Bacteroidetes ratio with probiotic and
synbiotic supplementation will be correlated with the
change observed in the metabolic variables.
Aim 5
To compare the effects of probiotic and synbiotic sup-
plements on gut microbiota, anthropometric, glycemic,
and lipid profiles. We hypothesize that synbiotic supple-
ments will have more efficacy to improve these indica-
tors than probiotic.
Methods/Design
Overview
A parallel-group randomized triple-blind placebo-
controlled clinical trial, designed according to the CON-
SORT SPIRIT 2013 guidelines (Additional file 1), will be
conducted over a period of 1.5 years from June 2016, in
Isfahan, Iran. We will include 120 prediabetic adults [indi-
viduals with impaired glucose tolerance (IGT) or impaired
fasting glucose (IFG)], as determined by the American
Diabetes Association (ADA) criteria [21]. The participants
will be selected from first-degree family of type 2 diabetic
patients. They will be recruited from the outpatient clinic
of Isfahan Endocrine and Metabolism Research Center.
Eligibility criteria for the participants are presented in
Table 1. A nutritionist will perform the intervention. The
participants will be randomized into three equal groups
using a blocking stratified sampling method by age and
sex to ensure equal numbers within each age and sex
strata using a computerized table of random digits. The
groups are probiotic, synbiotic (6 grams inulin + probiotic)
or placebo (maltodextrin) consumers for 6 months. The
appearance and packaging of the three products are iden-
tical. Details about the content and preparation process of
pruductes will be presented in section 3.2. The inulin dose
of 6 g/d as the prebiotic in the synbiotic type was selected
based on previous studies [22]. This dose was suggested
and tested to be well-tolerated. Participants, laboratory
staff, and investigators will be blinded to the allocation of
probiotic, synbiotic or placebo, which will be conducted
by the study pharmacist (who will then dispense blinded
supplements or placebo to the investigators). The subjects
will be instructed to dilute the powder in water and to
drink it after their main meal to minimize the killing of
the probiotic by gastric acid. Due to the dietary-controlled
nature of the study, water was selected as the beverage for
the delivery of supplements. Individuals will be appropri-
ately blinded in performing outcome measurements and
type of supplement. The supplements will be assigned let-
ter A, B or C and are otherwise identical. All of the partic-
ipants have been counseled to follow an energy-balanced
diet and physical activity recommendations 6 months pre-
vious to start of the study. They will be advised not to
modify their daily dietary and physical activity habits. To
ensure that these habits have not been modified during
the experiment, the participants will be instructed to rec-
ord daily food and physical activity diaries, which will be
checked monthly during face-to-face visits by a dietitian.
Also, the participants will be advised not to modify their
medication during the experiment. During these visits, the
researchers will check the compliance with the study sup-
plementation and the development of any adverse events.
Compliance will be assessed based on returned tablet
counts. The project coordinator will assess and manage
solicited and spontaneously reported adverse events of
trial interventions.
If a participant will be found to have missed >10% of
supplement dose at follow-up, he or she will be excluded
from the study. Also, the participants will be excluded from
the study if there is any change in medication, they start
antibiotics, or modify their lifestyle. The framework of the
study has been provided in Fig. 1. Study visits will be sched-
uled for weeks 1, 2, 3, 5, 7, 9, 12, 14, 16, 18, 20, 24, 48, and
72. A table of the time schedule of enrollment, interven-
tions, assessments, and visits for participants is provided in
Table 2, and an overview of the timeline of the study inter-
ventions and assessments is provided in Fig. 2.
Product standardization and palatability testing
Participants will be supplemented with 6 g/d of either syn-
biotics comprising a probiotic with an inulin-based pre-
biotic, probiotics containing the freeze-dried Lactobacillus
acidophilus, Bifidobacter bifidum, Bifidobacter lactis, and
Bifidobacter longum (109 for each) with maltodextrin as
filler, or placebo including maltodextrin for 6 months.
Table 1 Eligibility criteria for the effects of probiotic or synbiotic
supplementation on metabolic syndrome indices
Inclusion criteria:
Population: men and women 35–75 years old
Prediabetic [FBG = 100–125 OR 2hBS = 140–199 (via OGTT)]
Informed consent
Exclusion criteria:
Current smokers, suspected or definite history of alcohol or
drug abuse history
Antibiotic use in the past 3 months or during the treatment period
Using probiotic, prebiotic or symbiotic during the past 3 months
Noncompliance in consumption of the supplements
Being pregnant
Having gastrointestinal diseases, i.e., food allergies, celiac,
irritable bowel disease,
severe liver, kidney, heart, nervous system diseases
Allergy to studied agents
Currently taking prescribed nonsteroidal anti-inflammatory drugs,
antipsychotics, nicotinic acid
FBG fasting blood glucose, 2hBS 2-hour blood sugar, OGTT oral glucose
tolerance test
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Fig. 1 Study design schematic
Table 2 Time schedule of enrollment, interventions, assessments, and visits for participants
Week Visits and activities
Prior to starting the study Patients who meet eligibility criteria will be asked to read and sign the consent form
Week 1 Patients will be instructed on writing the food and physical activity records and procedures
for collection of stool samples. They will be asked not to take any other dietary supplementation
or probiotics and not to change their medication and/or lifestyle while in the study and to inform
the researchers if they are prescribed oral antibiotics at any time during the study
Week 2 Stool samples, food record and physical activity record will be collected. Weight, height, waist and
hip circumferences, and blood pressure will be measured. Biochemical tests will be performed.
The supplement will be delivered
Week 3, 5, 7, 9 Contact with the participants and effectiveness or adverse event will be recorded.
Week 12 Food record and physical activity record will be collected. Weight, height, waist and hip circumferences,
and blood pressure will be measured. Biochemical tests will be performed. The supplement will be delivered
Week 14, 16, 18, 20 Contact with the participants and effectiveness/adverse event will be recorded
Week 24 Stool samples, food record and physical activity record will be collected. Weight, height, waist and hip
circumferences, and blood pressure will be measured. Biochemical tests will be performed
Week 48, 72 Food record and physical activity record will be collected. Weight, height, waist and hip circumferences,
and blood pressure will be measured. Biochemical tests will be performed
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The supplements were prepared and packaged in Tak Gen
Zist Pharmaceutical Company, Tehran, Iran in sachet form.
All of microbial and purity tests were checked by two
independent microbiologists.
Prior to the onset of the trial, the solubility and palat-
ability of supplements (6 g dose) in a cup of water were
assessed to determine the optimal well-tolerated mode
of delivery of the supplement prescription.
The researchers will be in weekly contact with participants
and any concerns or side effects during the intervention
period will be addressed. The participants will be excluded
from the study if there is any side effect or problem.
Biochemical assays
Participants who have met the inclusion criteria (Table 1)
will be instructed to arrive at Isfahan Endocrine and Metab-
olism Research Center for laboratory testing between 7:00
and 9:00 am after a 12-hour overnight fast and not to do
vigorous physical activity for the previous 48 hours. Each
participant will be tested for the biochemical parameters at
baseline and during each follow-up visit (3, 6, 12, and
18 months).
An oral glucose tolerance test (OGTT) will be performed
to clarify glycemic status. Plasma lipid and lipoprotein con-
centrations (i.e., total cholesterol, high- and low-density
lipoprotein cholesterol, and triglycerides) will be measured
using a photometric assay kit (Pars Azmoon Co., Tehran,
Iran). Fasting glucose levels will be measured using the glu-
cose oxidase (GOD) method. Fasting insulin levels will be
measured using chemiluminescence (Siemens, Munich,
Germany). Ion exchange chromatography will be used to
test glycosylated hemoglobin (HbA1c).
The homeostatic model assessment of insulin resistance
(HOMA-IR) and homeostatic model assessment of beta-
cell function (HOMA-B) index will be used to determine
insulin resistance (primary outcome) and beta-cell function
respectively using the following formula:
HOMA‐IR ¼ fastingbloodglucose mmol=mlð Þ
 insulinassay microunit=mlð Þ=22:5
β cell function HOMA‐Bð Þ
¼ fasting insulin  20½ = fasting glucose‐3:5½ 
Anthropometric parameters and blood pressure
measurement
Height, weight, waist and hip circumferences will be
measured at baseline and will be repeated at months 3,
6, 12, and 18.
Height will be determined using a scale-mounted stadi-
ometer to the nearest 0.5 cm and weight will be measured
with light clothing to the nearest 0.1 kg. BMI will be cal-
culated by dividing each participant’s weight in kilograms
by height in meters squared. Waist circumference will be
measured at the midpoint between the lowest rib and the
iliac crest to the nearest 0.1 cm using a flexible tape. Hip
circumference will be measured around the widest portion
Fig. 2 Template of content for the schedule of enrollment, interventions, and assessments
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of the buttocks by the tape. The waist-to-hip ratio (WHR)
will be calculated according to World Health Organization
(WHO) recommendations [23]. All the measurements will
be taken by one person to decrease the error rate.
Blood pressure for each participant will be measured
by a trained nurse on two occasions using a mercury
sphygmomanometer in both of the hands and the mean
blood pressure readings will be used for the analysis ac-
cording to American Heart Association guidelines [24].
Participants will be instructed to rest for 10 minutes
prior to the first blood pressure measurement with a
minimum of 15 minutes between the two occasions.
Assessment of physical activity and dietary intake
Food and physical activity records will be assessed at five
time points during the study (at months 0, 3, 6, 12, and 18).
At each time point, participants will be instructed to record
their daily food and beverage intake for 3 days, including a
weekend day. To enhance portion size accuracy, food scales
and models will be also used. The portion sizes will be con-
verted to grams, and every food and beverage item will be
subsequently coded and analyzed for energy content, macro
and micro nutrients using Nutritionist 4 [25].
Physical activity will be assessed using the metabolic
equivalent of task (MET) questionnaire [26].
Assessment of gut microbiota
Fecal samples will be obtained daily for 3 days at baseline
and at the final 3 days of the intervention (after 6 months)
in sterile plastic containers and delivered to the Infectious
Diseases and Tropical Medicine Research Center Labora-
tory within 4 hours of collection. After being given a code,
samples will be immediately frozen at −80 °C until final
processing. DNA will be extracted from fecal samples (from
the 3 composite days mixed equally) using DNA Extraction
Stool Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. Numbers of phylum Firmi-
cutes and Bacteroidets will be determined by quantitative
real-time polymerase chain reactions (qPCR) methodology
using specific designed primers and Taqman probes.
The composition and ratio of the two fecal bacteria
before and after supplementation with probiotics, syn-
biotics, and placebo will be compared.
Data analysis
Sample size
Calculation of sample size was based on a parallel three-
group randomized clinical trial with repeated measurements
of main outcomes at three time points. Considering a type
one error rate of α ¼ 0:05 , and statistical power of 1 − β
= 0.80 (Z1− β = 0.84) for detecting a standardized effect size of
at least Δ= 0.60 in order to have the largest number of par-
ticipants in a repeated measures design structure based on
the following formula, 29 subjects were determined.
Compensating for possible attrition, 30% additional samples
will be recruited, in which a final 40 subjects in each study
group will participate.
R¼ 1þ w−1ð Þρ
w
−
vρ2
1þ v−1ð Þρ
 
; n1 repeated ¼ R
2ðz1−α=2 þ z1−βÞ2
Δ2
þ
z2
1−α=2
4
"
In this formula, Δ is the standardized effect size, R will
be determined based on number of observations before
intervention, v (in our study v = 1), number of observa-
tion after intervention, w (in the current study w = 2)
and intracluster correlation coefficient ρ, that was con-
sidered as ρ = 0.7 [27].
The participant’s adhesion and retention will be man-
aged by the project coordinator who will conduct weekly
contact. We anticipate that it will take 12 months to re-
cruit this sample size. All of the outcome data will be
collected even for participants who discontinue or devi-
ate from intervention protocols.
Randomization
A computer-generated list of random numbers is used
to create a series of sequentially numbered envelopes
containing equal assignments to either placebo, pro-
biotic or symbiotic. The study epidemiologist is respon-
sible for the randomization and the study pharmacist for
delivery of the blinded supplements. The supplements,
which will be assigned letter A, B or C, are otherwise
identical and the participants, investigators, outcome as-
sessors, and data analysts will be blinded after assign-
ment to interventions.
Statistical analysis
Record data including outcome data and adverse events
will be double-entered on SPSS software (Version [15],
SPSS Inc., Chicago, IL, USA) to secure its validity. De-
scriptive univariate analyses on all study variables
through presenting them as mean ± standard deviation
(SD) (for normally distributed continuous) or median
[interquartile range (IQR)] for nonnormal quantitative
data and frequency (percentage) for categorical data will
be conducted. Data will be evaluated for the presence of
outliers, violations of normality, and missing data. Major
violations of normality will be corrected with an appro-
priate transformation procedure, i.e., logarithmic trans-
formation for positively skewed and exponential
function for negatively skewed data. In the case of an
outlier, rather than transform the data, the outlier will
be “Winsorized,” that is, replaced by the most extreme
value in the tail of the distribution as well as a sensitivity
analysis being performed when outliers are in or out of
analyses. To test our hypothesis that probiotic and syn-
biotic supplementations will improve main outcomes in
prediabetic participants, a repeated measures analysis of
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variance (ANOVA) with a between-subject factors ap-
proach will be used. The multiple observations will be
considered as nested data within individuals. This will
allow us to make inference about time effects (i.e., com-
parison between the time points while accounting for
the correlation in the data) in each studied treatment
group and to make inference about differences between
competing treatment groups. This approach enables us
to make an inference regarding the group by time inter-
action as a primary important interested component. As
a perquisite, the assumption of sphericity will be evalu-
ated using a Muchly test, in the case of violation, multi-
variate or Huynh-Feldt approaches will be employed. A
compound symmetry error structure will be chosen for
this model when the assumption is present. We will use
repeated measures ANOVA as the main approach for
testing all our hypothesis regarding the main outcomes;
simultaneously, independent t test along with Bonferroni
adjustment will be conducted for comparing outcomes
in each follow-up time point between study groups.
Some prespecified subgroup analysis will be done based
on some confounding variables such as age, gender, etc.,
for detecting significant differences in intervention effi-
cacy across the strata of mentioned variables. However,
these subsamples will be compared to the main
dependent variables at baseline. If the groups are found
to be different from one another then they will be en-
tered into the model as a covariate. On the other hand,
the baseline values of the main dependent variables and
other potential confounding variables will be considered
as covariates and they will be adjusted in all fitted
models. The study analyst will have access to the results
and final trial dataset and make the final decision on in-
terim analyses and terminate the trial if there is any
harm for the participants.
Treatment of missing data
Missing data are common in longitudinal studies. Based
on patterns and the mechanism of missing data, an ap-
propriate multiple imputation approach will be followed
for completing missing data. We will use an intention-
to-treat analysis as our primary analytic approach. As an
alternative statistical analysis method using linear mixed
model ANOVAs or generalized estimating equation
(GEE) for longitudinal analysis, we will compare main
study outcomes across the treatment groups. Through
employing these methods, the possibility for using all
available data to construct weighted averages across the
different patterns of missing data to provide valid point
estimates, and confidence intervals for population pa-
rameters will be provided [28]. As a secondary analysis,
we will conduct a per protocol analysis and restrict the
analyses to only those individuals who complete the
intervention; if the results differ we will interpret the
findings based on the intention-to-treat analysis.
Discussion
Up to now, the therapeutic effects of gut microbiota ma-
nipulation, through the administration of probiotics/pre-
biotics/synbiotics, have been discussed, but there is little
information regarding if they improve metabolic indica-
tors in humans. In addition, the potential benefits of
these biopharmaceuticals in prediabetic individuals who
are at high risk for developing type 2 diabetes and ex-
periencing cardiovascular events has received little at-
tention. This trial will address this important research
gap, by exploring and comparing the role of probiotics
and synbiotics in modifying anthropometric, glycemic,
and lipid profiles among prediabetic individuals.
The innovative aspects of this clinical trial include: (1)
testing hypotheses involving a novel concept for which
there are little strong data in humans; (2) focusing on in-
dividuals at high risk for T2DM, including those with
prediabetes; (3) carrying out a synthesis and study of
synbiotics for the first time in Iran; (4) following up the
participants for 1 year after the intervention phase; and
(5) comparing the effects of probiotics and synbiotics.
Importantly, our findings could have a significant impact
on clinical practice and public health as a simple and effica-
cious adjunctive approach for prevention or management of
T2DM if our hypotheses are supported. The primary chal-
lenge of our study will be participant adhesion and retention.
This challenge will be managed by the project coordinator
who will have weekly contact with participants in which any
concerns or issues will be immediately addressed.
If these supplements are shown to be effective in man-
agement of prediabetes and preventing diabetes, they
would be a very attractive alternative or adjunctive for
current medications.
Trial status
Estimated enrollment is 120 participants.
The study start date was June 2016, and estimated
study completion date is June 2018.
Additional file
Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents. (DOCX 76 kb)
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